Coya Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 18, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 18, 2025

COYA$3.16-5.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2024 and 2023

BALANCE SHEETS

	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$38,339,762	$32,626,768
Collaboration receivables	-	7,500,000
Prepaids and other current assets	5,968,666	1,069,557
Total current assets	44,308,428	41,196,325
Fixed assets, net	38,588	65,949
Total assets	$44,347,016	$41,262,274
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$1,588,128	$1,155,656
Accrued expenses	1,388,060	2,973,215
Deferred collaboration revenue	848,286	923,109
Total current liabilities	3,824,474	5,051,980
Deferred collaboration revenue	945,447	574,685
Total liabilities	4,769,921	5,626,665
Commitments and contingencies (Note 7)
Stockholders' equity:
Series A convertible preferred stock, $0.0001 par value: 10,000,000 shares authorized, none issued and outstanding as of December 31, 2024 and 2023	-	-
Common stock, $0.0001 par value; 200,000,000 shares authorized; 16,707,441 and 14,405,325 shares issued and outstanding as of December 31, 2024 and 2023, respectively	1,671	1,441
Additional paid-in capital	80,312,594	61,501,801
Subscription receivable	-	(11,250)
Accumulated deficit	(40,737,170)	(25,856,383)
Total stockholders' equity	39,577,095	35,635,609
Total liabilities and stockholders' equity	$44,347,016	$41,262,274

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.